Disclosures. Premalignant Lesions of the Breast: What Clinicians Want and Why. NY Times: Prone to Error: Earliest Steps to Find Cancer.
|
|
- Kerry Robertson
- 5 years ago
- Views:
Transcription
1 Disclosures Premalignant Lesions of the Breast: What Clinicians Want and Why I have nothing to disclose Rick Baehner, MD Assistant Professor, UCSF Pathology NY Times: Prone to Error: Earliest Steps to Find Cancer 3 Agenda Discussion of clinical significance of premalignant lesions of the breast focusing on: atypical ductal hyperplasia and ductal carcinoma in situ The important prognostic factors in ductal carcinoma in situ Discussion of Oxford overview of DCIS trials: what does this data tell us about the standard clinical and pathologic covariates? The importance of predictive factors, i.e., estrogen receptor testing in DCIS 4 Now she was being told the pathologist had made a mistake. Her new doctor was certain she never had the disease, called ductal carcinoma in situ, or D.C.I.S. It had all been unnecessary the surgery, the radiation, the drugs and, worst of all, the fear 1
2 5 6 Introduction: DCIS Has Increased Markedly Since the Advent of Mammographic Screening What Clinicians Need to Know Incidence rate (per,) Figure 2. SEER9 Age-adjusted incidence rate of breast cancer by stage (1973-5) Localized Regional In Situ Metastatic Year of diagnosis In situ Rate Localized Rate Regional Rate Distant Rate Following Biopsy: Is it cancer or not (UDH, ALH, LCIS, ADH, DCIS, IBC)? Do they need to excise the area? What is the appropriate surgery (size; margin control)? Lumpectomy Mastectomy Following Excision: Is additional surgery required? What is the likelihood of local regional recurrence? Do they need to do radiation therapy? Do they need to offer tamoxifen? Courtesy of Dr. Laura Esserman 7 8 NCCN Guidelines Case Presentation #1 A 58 y/o post-menopausal woman has an abnormal screening mammogram with prior normal annual screening mammograms in the past Diagnostic mammogram shows fine calcifications in a segmental distribution, BIRADS 4 She had no palpable masses or lymph adenopathy on exam No family history of breast cancer 2
3 9 BIRADS Categories Breast Imaging Reporting and Data System: A tool to standardize mammography reporting and facilitate outcome monitoring : Needs additional imaging (diagnostic mammogram or prior mammograms) 1: Negative 2: Benign 3: Probably benign (2% malignant); short interval follow up recommended 4: Suspicious abnormality; should consider biopsy 5: Highly suggestive of malignancy (95% malignant); appropriate action should be taken 6: Known malignancy Stereotactic core biopsy showed: Adv Anat Pathol. 3 May;(3): Adv Anat Pathol. 3 May;(3):
4 13 14 Adv Anat Pathol. 3 May;(3): Differential Diagnosis & Recommendation Is the H&E sufficient for diagnosis? UDH, CCH, FEA ADH, CCH, FEA DCIS, CCH, FEA Are there other studies that might be useful? Level H&E sections IHC: basal/luminal cytokeratins Clinical recommendation? 4
5 Guidelines for Evaluation of Proliferative Ductal Pattern Lesions Usual Ductal Hyperplasia Florid hyperplasia without atypia has swirling streaming patterns of cells. There is irregularity of nuclear shape, chromasia, and position, and there are irregular, often ragged, serpigninous slit-like secondary spaces, most marked centrally. Intercellular borders are usually ill defined. 17 Usual Ductal Hyperplasia 18 Human Pathol 1992;23():95-97 Guidelines for Evaluation of Proliferative Ductal Pattern Lesions Ductal Carcinoma In Situ Population of evenly spaced, uniform cells with uniformly oval to rounded nuclear features, comprising without doubt the entire population throughout two membranebound spaces. Cytoplasm is pale and intracellular borders are usually distinct. 2 nd spaces have smooth, rounded punched-out borders (cribriform architecture and rigid, nontapering bars can be found. An overall size criterion is a useful adjunct. 19 Human Pathol 1992;23():
6 Guidelines for Evaluation of Proliferative Ductal Pattern Lesions Atypical Ductal Hyperplasia Exhibits partial involvement of the basement membrane-bound space by a cell population of the type defined for DCIS, noncomedo type. The nonatypical cell population consists of columnar, polarized cells of the type usually seen in the ductal lamina positions immediately above the basement membrane. The bothersome cells need to constitute an entire bar crossing a space or at least a cell population of six or seven cells across When in doubt between ADH and DCIS use the more benign designation Human Pathol 1992;23(): Sent out ductal and 7 lobular borderline lesions There was not a single case in which all pathologists agreed 6 cases that ranged the gamut of hyperplasia to CIS Significant bias of pathologists: benign or malignant Rosai J. Am J Surg Pathol Mar;15(3):9-21. Teaching set 15 slides, written set of definitions, illustrations Complete agreement among all 6 observers 14/24; >5 observers same dx in 17/24; >4 observers same dx in 22/24 (92%) Agreement between diagnoses of 5 pathologists with Dr. Page: 92%, 88%, 79%, 71%, 88% Schnitt SJ, Connolly JL, Tavassoli FA, Fechner RE, Kempson RL, GelmanR, Page DL. Am J Surg Pathol Dec;16(12):
7 Characterization of Breast Cells Distinction of ADH 25. N Engl J Med 1985;312: Numerous studies have shown the proliferating epithelium of UDH in fibrocystic change will react with both basal (CK 5, 5/6, 14, 17) and luminal type (CK 18, 19) cytokeratins Low grade DCIS are usually negative for basal cytokeratins and positive for luminal type cytokeratins (CK 18, 19) CK 5/6 CK 18 CK 19 Jarasch ED. Hum Pathol Mar;19(3): Otterbach F. Histopathology. Sep;37(3):232- Moinfar F. Am J Surg Pathol Sep;23(9): , 9 individuals 2,942 women with atypical breast lesions Mean Age Dx: 53 years (range: 19-93) Mean FU all: 66 months 7
8 29 Case Presentation #1 Conclusions Patients with ADH are at greater risk of local regional recurrence when compared to UDH patients Distinction of ADH from UDH and DCIS is a clinically significant distinction Use of clinically validated criteria for distinction of UDH, ADH and DCIS are warranted When in doubt between ADH and DCIS use the more benign designation Case Presentation #2 A y/o peri-menopausal woman has an abnormal screening mammogram Diagnostic mammogram shows coarse pleomorphic calcifications in a segmental distribution, BIRADS 5 She had slight palpable mass but no adenopathy on exam She has no family history of breast cancer 8
9 Differential Diagnosis & Recommendation Diagnostic markers DCIS Invasive ductal carcinoma Prognostic markers Tumor size, margins, nuclear grade, comedo necrosis, histologic subtype Predictive markers ER/PR Recommendations 9
10 17:41:28 9 Sep 9 Provisional results: subject to revision (Name: gr_cis_sc_rt_rlili_all_) 17:42:3 9 Sep 9 Provisional results: subject to revision (Name: gr_cis_sc_rt_rlilii_all_) 17:42:38 9 Sep 9 Provisional results: subject to revision (Name: gr_cis_sc_rt_rllic_all_) (Name: gr_cis_sc_rt_bcdth_all_) (Name: gr_cis_sc_rt_dead_all_) (Name: gr_cis_sc_rt_heart_all_) Oxford Overview of Randomized Trials of BCS±RT for DCIS Oxford Overview of Randomized Trials of BCS±RT for DCIS Ips. BREAST RECURRENCE (CIS & Inv) (%) DCIS: BCS + RT vs. BCS Ips. BREAST RECURRENCE (CIS & Inv) 3723 women 5-year gain.5 % (SE 1.2) -year gain 15.2 % (SE 1.6) logrank 2p < BCS 28.1% BCS+RT 12.9% 5 15 Years since randomisation Ips. BREAST RECURRENCE (Inv only) (%) DCIS: BCS + RT vs. BCS Ips. BREAST RECURRENCE (Inv only) 3723 women 5-year gain 5.4 % (SE.8) -year gain 8.5 % (SE 1.3) logrank 2p < BCS 15.4% BCS+RT 6.8% 5 15 Years since randomisation Ips. BREAST RECURRENCE (CIS only) (%) DCIS: BCS + RT vs. BCS Ips. BREAST RECURRENCE (CIS only) 3723 women 5-year gain 5.8 % (SE.9) -year gain 8.4 % (SE 1.2) logrank 2p < BCS 14.9% BCS+RT 6.5% 5 15 Years since randomisation BREAST CANCER MORTALITY (%) DCIS: BCS + RT vs. BCS BREAST CANCER MORTALITY 3726 women 5-year loss.4 % (SE.4) -year loss.5 % (SE.8) logrank 2p >.1; NS :46:8 9 Sep 9 Provisional results: subject to revision BCS+RT 4.1% BCS 3.7% 5 15 Years since randomisation ANY DEATH (%) 3726 women DCIS: BCS + RT vs. BCS ANY DEATH 5-year loss.1 % (SE.6) -year loss.2 % (SE 1.1) logrank 2p >.1; NS BCS+RT 8.4% 2.8 BCS 8.2% Years since randomisation 17:46:47 9 Sep 9 Provisional results: subject to revision HEART DISEASE MORTALITY (%) DCIS: BCS + RT vs. BCS HEART DISEASE MORTALITY 3723 women 5-year gain.1 % (SE.3) -year loss.1 % (SE.5) logrank 2p >.1; NS.6 BCS+RT 1.5% BCS % 15 Years since randomisation 17:49:38 9 Sep 9 Provisional results: subject to revision 4 Landmark DCIS Trials: B17, EORTC 853, SweDCIS, DCIS UK J Natl Cancer Inst Monogr. ;(41): Review. 4 Landmark DCIS Trials: B17, EORTC 853, SweDCIS, DCIS UK J Natl Cancer Inst Monogr. ;(41): Review. 39 Prognosis: DCIS & Tumor Size Histologic Grade: EORTC 853 Of the 4 landmark DCIS trials of local excision (LE) versus LE + radiotherapy two reported histologic grade to be associated with the risk of local regional recurrence Br J Cancer. Jun 29;3(1):94-. Epub Jun 1. J Clin Oncol. 1 Apr 15;19(8): J Clin Oncol. 6 Jul ;24(21): Epub 6 Jun 26.
11 Oxford Overview of Randomized Trials of BCS±RT for DCIS Patient Subset Identified A Priori As Potentially At Low Risk: Low Nuclear Grade, Negative Margins, Path Tumor Size < mm ECOG 5194: Histologic Grade local excision (LE) alone 42 Low & Intermediate Grade < 2.5 cm in greatest dimension High Grade < 1. cm in greatest dimension Presented NIH DCIS Conference, 9 Darby, JNCI Monograph, J Clin Oncol. 9 Nov ;27(32): Epub 9 Oct 13. College of American Pathologists DCIS Nuclear Grading System 43 Comedo Necrosis NSABP B17: local excision (LE) versus LE + radiotherapy 44 Grade 1 Grade 3 Grade 2 NSABP definition: Absent % Slight <% Moderate /Marked % Patients with Moderate /Marked % had 2-fold higher risk or LRR 1-Arch Pathol Lab Med Vol 133, January 9 Cancer Aug 1;86(3):
12 45 46 J Natl Cancer Inst Monogr. ;(41): Review. Margin Status Women for whom the surgical margins were close (<2 mm) were classified as having negative surgical margins. Tamoxifen NSABP B-24 Established benefit of tamoxifen in DCIS treated with lumpectomy and radiation Demonstrated a small but significant reduction of local invasive recurrence as well as contralateral breast cancer when used for 5 years. 8.2% in tamoxifen group versus 13.4% in placebo Tamoxifen resulted in absolute 5 year lowering of ipsilateral events by 3.3% and contralateral events by 1.4% Study initiated before clear relationship established between ER/PR+ disease and effectiveness of hormone therapy Fisher B, et al. Lancet 1999; 353: NSAPB B-17 AND B-24 All IBTR Invasive IBTR 47 Proportion Disease-Free TIME TO FIRST BREAST CANCER EVENT IN NSABP B ER-pos tamoxifen (n=264) ER-pos placebo (n=257) ER-neg tamoxifen (n=87) ER-neg placebo (n=66) Wapnir, ASCO, 7 Years Since Surgery Recommend use of ASCO/CAP cutoffs for DCIS ER assessment Courtesy of L Solin Allred, San Antonio, 2 J Clin Oncol. 12 Apr ;(12): Epub 12 Mar 5. 12
13 Case Presentation #2 Conclusions 49 Summary DCIS Most consistent prognostic variable is DCIS tumor size however nuclear grade and percentage of comedo necrosis should be carefully documented using CAP guidelines Margins 2. mm have significantly lower risk of local regional recurrence ER status is important for identification of patients who will benefit from hormonal therapy with reduced local regional recurrence risk Careful distinction between UDH, ADH and low grade DCIS is critical in patient management as ADH differs in clinical outcome and is often is managed surgically whereas DCIS is often is managed with radiotherapy Prognostic factors including: patient age, tumor size, comedo necrosis, nuclear grade and margin status are the most important prognostic covariates and need to be carefully assessed using current guidelines Assessment of ER has been shown in DCIS to be associated with both ipsilateral and contralateral recurrence risk reduction 51 Thank you 13
Radiation and DCIS. The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging
Radiation and DCIS The 16 th Annual Conference on A Multidisciplinary Approach to Comprehensive Breast Care and Imaging Einsley-Marie Janowski, MD, PhD Assistant Professor Department of Radiation Oncology
More informationBREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO
BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO Chairman Department of Radiation Oncology Albert Einstein Medical Center Philadelphia, PA Professor (Adjunct)
More informationBREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO
BREAST CONSERVATION TREATMENT IN EARLY STAGE DISEASE AND DCIS LAWRENCE J. SOLIN, MD, FACR, FASTRO Chairman Department of Radiation Oncology Albert Einstein Healthcare Network Philadelphia, PA Professor
More informationInterpretation of Breast Pathology in the Era of Minimally Invasive Procedures
Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine Jacksonville Medical Director, UF Health Breast Center Chief of Pathology
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationPathology of Lobular & Ductal Preneoplasia. Syed A Hoda, MD Weill-Cornell, New York, NY
Pathology of Lobular & Ductal Preneoplasia Syed A Hoda, MD Weill-Cornell, New York, NY Proliferative Epithelial Changes in Breast A wide range of proliferative epithelial changes occur in the breast There
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationDuctal Carcinoma in Situ. Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA
Ductal Carcinoma in Situ Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Definition of DCIS WHO 2012 A neoplastic proliferation
More informationColumnar Cell Lesions
Columnar Cell Lesions Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Question? Columnar cell lesions are: a) Annoying lesions
More informationCLINICAL SIGNIFICANCE OF BENIGN EPITHELIAL CHANGES
Papillomas. Papillomas are composed of multiple branching fibrovascular cores, each having a connective tissue axis lined by luminal and myoepithelial cells ( Fig. 23-11 ). Growth occurs within a dilated
More informationColumnar Cell Lesions. Columnar Cell Lesions and Flat Epithelial Atypia
Columnar Cell Lesions and Stuart J. Schnitt, M.D. Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA, USA Columnar Cell Lesions Lesions characterized by columnar epithelial cells
More informationPersonalized Treatment of DCIS
Global Breast Cancer Conference 2016 [The Shilla Hotel, Jeju] Symposium 1 : DCIS - What s New? (14:40-15:50) Personalized Treatment of DCIS 2016. 4. 28. Breast Division, Department of Surgery Sungkyunkwan
More informationProliferative Breast Disease: implications of core biopsy diagnosis. Proliferative Breast Disease
Proliferative Breast Disease: implications of core biopsy diagnosis Jean F. Simpson, M.D. Breast Pathology Consultants, Inc. Nashville, TN Proliferative Breast Disease Must be interpreted in clinical and
More informationMammographic imaging of nonpalpable breast lesions. Malai Muttarak, MD Department of Radiology Chiang Mai University Chiang Mai, Thailand
Mammographic imaging of nonpalpable breast lesions Malai Muttarak, MD Department of Radiology Chiang Mai University Chiang Mai, Thailand Introduction Contents Mammographic signs of nonpalpable breast cancer
More informationProliferative Epithelial lesions of the Breast. Sami Shousha, MD, FRCPath Charing Cross Hospital & Imperial College, London
Proliferative Epithelial lesions of the Breast Sami Shousha, MD, FRCPath Charing Cross Hospital & Imperial College, London Amman, November2013 Proliferative Epithelial Lesions of the Breast Usual type
More informationLOBULAR CARCINOMA IN SITU: WHAT DOES IT MEAN? THE SURGEON'S PERSPECTIVE
: WHAT DOES IT MEAN? THE SURGEON'S PERSPECTIVE Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University of Washington Joint Member, Fred Hutchinson Cancer
More informationSpeaker s Bureau. Travel expenses. Advisory Boards. Stock. Genentech Invuity Medtronic Pacira. Faxitron. Dune TransMed7 Genomic Health.
Management of DCIS Shawna C. Willey, MD, FACS Professor of Surgery, Georgetown University Director, Medstar Regional Breast Health Program Chief, Department of Surgery Medstar Georgetown University Hospital
More informationBalancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006
Balancing Evidence and Clinical Practice in the Treatment of Localized Breast Cancer May 5, 2006 Deborah Hamolsky MS, RN : DCIS Carol Franc Buck Breast Care Center UCSF Comprehensive Cancer Center Jane
More information04/10/2018 HIGH RISK BREAST LESIONS. Pathology Perspectives of High Risk Breast Lesions ELEVATED RISK OF BREAST CANCER HISTORICAL PERSPECTIVES
Pathology Perspectives of High Risk Breast Lesions Savitri Krishnamurthy MD Professor of Pathology Deputy Division Head Director of Clinical Trials, Research and Development The University of Texas MD
More information3/27/2017. Disclosure of Relevant Financial Relationships. Papilloma???
Management of Papillary Lesions Diagnosed at Rad Path Concordant Core Biopsy (CNB) Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to
More informationSurgical Pathology Issues of Practical Importance
Surgical Pathology Issues of Practical Importance Anne Moore, MD Medical Oncology Syed Hoda, MD Surgical Pathology The pathologist is central to the team approach needed to manage the patient with breast
More informationIn Situ Breast Carcinoma. James L. Connolly, M.D Beth Israel Deaconess Medical Center Professor of Pathology Harvard Medical School Boston, MA
In Situ Breast Carcinoma James L. Connolly, M.D Beth Israel Deaconess Medical Center Professor of Pathology Harvard Medical School Boston, MA Content In Situ Ductal Carcinoma In Situ Lobular Carcinoma
More informationCase #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).
SOLID TUMORS WORKSHOP Cases for review Prostate Cancer Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). January 2009 PSA 4.4, 20% free; August 2009 PSA 5.2; Sept 2009
More informationDuctal Carcinoma in Situ (DCIS)
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Ductal Carcinoma in Situ (DCIS) Ductal Carcinoma in Situ DCIS Versions 2002 2017: Audretsch / Blohmer / Brunnert / Budach /
More informationEpithelial Columnar Breast Lesions: Histopathology and Molecular Markers
29th Annual International Conference Advances in the Application of Monoclonal Antibodies in Clinical Oncology and Symposium on Cancer Stem Cells 25 th -27t h June, 2012, Mykonos, Greece Epithelial Columnar
More informationCytyc Corporation - Case Presentation Archive - March 2002
FirstCyte Ductal Lavage History: 68 Year Old Female Gail Index: Unknown Clinical History: Negative Mammogram in 1995 6 yrs. later presents with bloody nipple discharge Subsequent suspicious mammogram Suspicious
More informationTreatment options for the precancerous Atypical Breast lesions. Prof. YOUNG-JIN SUH The Catholic University of Korea
Treatment options for the precancerous Atypical Breast lesions Prof. YOUNG-JIN SUH The Catholic University of Korea Not so benign lesions? Imaging abnormalities(10% recall) lead to diagnostic evaluation,
More informationMousa. Israa Ayed. Abdullah AlZibdeh. 0 P a g e
1 Mousa Israa Ayed Abdullah AlZibdeh 0 P a g e Breast pathology The basic histological units of the breast are called lobules, which are composed of glandular epithelial cells (luminal cells) resting on
More informationBenign Breast Disease and Breast Cancer Risk
Benign Breast Disease and Breast Cancer Risk Jean F. Simpson, M.D. Vanderbilt University Nashville, Tennessee December 1, 2011 Nashville Nashville Lebanon 1 Cedars of Lebanon State Park The American University
More informationDuctal Carcinoma-in-Situ: New Concepts and Controversies
Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationBreast Pathology. Breast Development
Breast Pathology Lecturer: Hanina Hibshoosh, M.D. Reading: Kumar, Cotran, Robbins, Basic Pathology, 6th Edition, pages 623-635 Breast Development 5th week - thickening of the epidermis - milk line 5th
More informationPapillary Lesions of the Breast: WHO Update
Papillary Lesions of the Breast: WHO Update Stuart J. Schnitt, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA, USA Papillary Lesions of the Breast
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationEnterprise Interest None
Enterprise Interest None B3 lesions of the breast What are they at surgery? Case 4 Edi Brogi MD PhD Attending Pathologist - Director of Breast Pathology Memorial Sloan Kettering Cancer Center New York
More informationPromise of a beautiful day
Promise of a beautiful day Ductal carcinoma in Situ Lobular Carcinoma in Situ Natural History Manosmed Tartous Oct 2009 Gérard ABADJIAN MD Pathology Department Hôtel-Dieu de France. Associate Professor
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationDisclosures 5/27/2012. Outline of Talk. Outline of Talk. When Is LCIS Clinically Significant? Classic LCIS. Classic LCIS
When Is LCIS Clinically Significant? Disclosures I have nothing to disclose Yunn-Yi Chen, MD, PhD Professor Outline of Talk Outline of Talk Classic LCIS Classic LCIS Definition of lobular differentiation
More informationCase study 1. Rie Horii, M.D., Ph.D. Division of Pathology Cancer Institute Hospital, Japanese Foundation for Cancer Research
NCCN/JCCNB Seminar in Japan April 15, 2012 Case study 1 Rie Horii, M.D., Ph.D. Division of Pathology Cancer Institute Hospital, Japanese Foundation for Cancer Research Present illness: A 50y.o.premenopausal
More informationIncidence of ductal lesions
Ductal Proliferative Lesions of the Breast: From FEA to ADH to DCIS Incidence of ductal lesions Pre-mammography: DCIS < 3% of breast cancers, large palpable masses, with invasion Mammography: DCIS 25%
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More information10 reasons why it makes sense to rename DCIS to minimise overtreatment? PRO: Mike Dixon OBE Edinburgh Breast Unit
10 reasons why it makes sense to rename DCIS to minimise overtreatment? PRO: Mike Dixon OBE Edinburgh Breast Unit 10 reasons why it makes sense to rename DCIS to minimise overtreatment? PRO: Mike Dixon
More informationBreast Cancer: Selected Topics for the Primary Care Clinician
Breast Cancer: Selected Topics for the Primary Care Clinician Leah Karliner, MD MAS October 2009 Primary Care Medicine: Principles and Practice OUTLINE Incidence and Mortality Risk Factors and Risk Reduction/Prevention
More informationBruno CUTULI Policlinico Courlancy REIMS. WORKSHOP SULL IRRADIAZIONE MAMMARIA IPOFRAZIONATA Il carcinoma duttale in situ
Bruno CUTULI Policlinico Courlancy REIMS WORKSHOP SULL IRRADIAZIONE MAMMARIA IPOFRAZIONATA Il carcinoma duttale in situ XXI CONGRESSO AIRO GENOVA 22.11.2011 INTRODUCTION Due to wide diffusion of mammography,
More informationCase Scenario 1 History and Physical 3/15/13 Imaging Pathology
Case Scenario 1 History and Physical 3/15/13 The patient is an 84 year old white female who presented with an abnormal mammogram. The patient has a five year history of refractory anemia with ringed sideroblasts
More informationColumnar Cell Lesions and Flat Epithelial Atypia
Columnar Cell Lesions and Flat Epithelial Atypia Laura C. Collins, M.D. Department of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA Terminology for Columnar Cell
More informationTriple Negative Breast Cancer
Triple Negative Breast Cancer Prof. Dr. Pornchai O-charoenrat Division of Head-Neck & Breast Surgery Department of Surgery Faculty of Medicine Siriraj Hospital Breast Cancer Classification Traditional
More informationGood afternoon everyone. First of all many thanks to Dr. Bonaventura and Dr. Arn for inviting
PATHOLOGY IN-SITU CARCINOMA, ROHIT BHARGAVA, MD 1 Good afternoon everyone. First of all many thanks to Dr. Bonaventura and Dr. Arn for inviting me here, it s great to be here and I m going to talk about
More informationBreast pathology. 2nd Department of Pathology Semmelweis University
Breast pathology 2nd Department of Pathology Semmelweis University Breast pathology - Summary - Benign lesions - Acute mastitis - Plasma cell mastitis / duct ectasia - Fat necrosis - Fibrocystic change/
More informationCase 1. BREAST CANCER From Diagnosis to Treatment: The Role of Primary Care
BREAST CANCER From Diagnosis to Treatment: The Role of Primary Care Leah Karliner, MD MAS University of California San Francisco Primary Care Medicine Update 2009 April 2009 Case 1 AR, a 60 year old African
More information04/10/2018. Intraductal Papillary Neoplasms Of Breast INTRADUCTAL PAPILLOMA
Intraductal Papillary Neoplasms Of Breast Savitri Krishnamurthy MD Professor of Pathology Deputy Division Head The University of Texas MD Anderson Cancer Center 25 th Annual Seminar in Pathology Pittsburgh,
More informationDisclosure. Objectives 03/19/2019. Current Issues in Management of DCIS Radiation Oncology Considerations
Current Issues in Management of DCIS Radiation Oncology Considerations Fariba Asrari, M.D. Director. Johns Hopkins Breast Center at Green Spring Station Department of Radiation Oncology & Molecular Sciences
More informationWhen do you need PET/CT or MRI in early breast cancer?
When do you need PET/CT or MRI in early breast cancer? Elizabeth A. Morris MD FACR Chief, Breast Imaging Service Memorial Sloan-Kettering Cancer Center NY, NY Objectives What is the role of MRI in initial
More informationThe Hot Topic for today is a biopsy from a 58-year-old woman who had worrisome mammographic calcifications on screening.
The Hot Topic for today is a biopsy from a 58-year-old woman who had worrisome mammographic calcifications on screening. 1 My name is Dan Visscher; I am a consultant in the Division of Anatomic Pathology
More informationANCO s 2011 San Antonio Breast Cancer Symposium Highlights. Michael Alvarado, M.D. Disclosure
ANCO s 2011 San Antonio Breast Cancer Symposium Highlights Michael Alvarado, M.D. FACS Assistant Professor of Surgery UCSF Michael Alvarado, M.D. Disclosure Advisory Board Member Genomic Health DCIS Study
More informationCase Scenario 1. 2/15/2011 The patient received IMRT 45 Gy at 1.8 Gy per fraction for 25 fractions.
Case Scenario 1 1/3/11 A 57 year old white female presents for her annual mammogram and is found to have a suspicious area of calcification, spread out over at least 4 centimeters. She is scheduled to
More informationPapillary Lesions of the breast
Papillary Lesions of the breast Emad Rakha Professor of Breast Pathology The University of Nottingham Papillary lesions of the breast are a heterogeneous group of disease, which are characterised by neoplastic
More informationBREAST PATHOLOGY. Fibrocystic Changes
BREAST PATHOLOGY Lesions of the breast are very common, and they present as palpable, sometimes painful, nodules or masses. Most of these lesions are benign. Breast cancer is the 2 nd most common cause
More informationDuctal Proliferations of the Breast: The Good, the Bad, and the Ugly
Ductal Proliferations of the Breast: The Good, the Bad, and the Ugly Melinda F. Lerwill, MD CRITERIA FOR DISTINGUISHING LOW-GRADE DUCTAL CARCINOMA IN SITU FROM USUAL DUCTAL HYPERPLASIA CYTOLOGY Low-grade
More information57th Annual HSCP Spring Symposium 4/16/2016
An Unusual Malignant Spindle Cell Lesion to Involve the Breast Erinn Downs-Kelly, D.O. Associate Professor of Pathology University of Utah & ARUP Laboratories No disclosures Case 39 y/o female with no
More informationACRIN 6666 Therapeutic Surgery Form
S1 ACRIN 6666 Therapeutic Surgery Form 6666 Instructions: Complete a separate S1 form for each separate area of each breast excised with the intent to treat a cancer (e.g. each lumpectomy or mastectomy).
More informationPapillary Lesions of the Breast A Practical Approach to Diagnosis. (Arch Pathol Lab Med. 2016;140: ; doi: /arpa.
Papillary Lesions of the Breast A Practical Approach to Diagnosis (Arch Pathol Lab Med. 2016;140:1052 1059; doi: 10.5858/arpa.2016-0219-RA) Papillary lesions of the breast Span the spectrum of benign,
More informationRecurrence following Treatment of Ductal Carcinoma in Situ with Skin-Sparing Mastectomy and Immediate Breast Reconstruction
Recurrence following Treatment of Ductal Carcinoma in Situ with Skin-Sparing Mastectomy and Immediate Breast Reconstruction Aldona J. Spiegel, M.D., and Charles E. Butler, M.D. Houston, Texas Skin-sparing
More informationLYMPHATIC DRAINAGE AXILLARY (MOSTLY) INTERNAL MAMMARY SUPRACLAVICULAR
BREAST LYMPHATIC DRAINAGE AXILLARY (MOSTLY) INTERNAL MAMMARY SUPRACLAVICULAR HISTOLOGY LOBE: (10 in whole breast) LOBULE: (many per lobe) ACINUS/I, aka ALVEOLUS/I: (many per lobule) DUCT(S): INTRA- or
More informationContemporary Classification of Breast Cancer
Contemporary Classification of Breast Cancer Laura C. Collins, M.D. Vice Chair of Anatomic Pathology Professor of Pathology Beth Israel Deaconess Medical Center and Harvard Medical School Boston, MA Outline
More informationBenign, Reactive and Inflammatory Lesions of the Breast
Benign, Reactive and Inflammatory Lesions of the Breast Marilin Rosa, MD Associate Member Section Head of Breast Pathology Department of Anatomic Pathology Program Director, Breast Pathology Fellowship
More informationNational Diagnostic Imaging Symposium 2013 SAM - Breast MRI 1
National Diagnostic Imaging Symposium 2013 December 8-12, 2013 Disney s Yacht Club Resort Lake Buena Vista, Florida Self Assessment Module Questions, Answers and References Day SAM Title - Each SAM title
More informationImage guided core biopsies:
Recommendations on the Surgical, Radiologic and Pathologic Approaches to Breast Disease: Using best practices based on multidisciplinary methodologies developed through the Allina Breast Committee. Image
More informationThe Trials and Tribulations of Chasing a COMET
The Trials and Tribulations of Chasing a COMET AUS/NZ Breast Cancer Trials Group 39 th Annual Scientific Meeting July 28, 2017 E. Shelley Hwang MD MPH Duke University Medical Center This is DCIS 67 year
More informationProphylactic Mastectomy State of the Art
Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 6 th Brazilian Breast Cancer Conference Sao Paulo, Brazil 9 March 2012 Prophylactic Mastectomy State of the Art Monica Morrow
More information6/3/2010. Outline of Talk. Lobular Breast Cancer: Definition of lobular differentiation. Common Problems in Diagnosing LCIS in Core Biopsies
Outline of Talk Lobular Breast Cancer: Common Problems in Diagnosing LCIS in Core Biopsies Definition of lobular differentiation Variants of LCIS that: carry risk for unsampled invasive cancer mimic DCIS
More informationUse of a Protease Activated System for Real-time Breast Cancer Lumpectomy Margin Assessment
Use of a Protease Activated System for Real-time Breast Cancer Lumpectomy Margin Assessment Barbara L. Smith, MD, PhD Professor of Surgery, Harvard Medical School Division of Surgical Oncology Massachusetts
More informationCarcinoma mammario: le istologie non frequenti. Valentina Guarneri Università di Padova IOV-IRCCS
Carcinoma mammario: le istologie non frequenti Valentina Guarneri Università di Padova IOV-IRCCS Histological diversity of breast adenocarcinomas Different histological types are defined according to specific
More informationJose A Torres, MD 1/12/2017
Jose A Torres, MD 1/12/2017 Background Globally leading cause of cancer related death in women ~249,000 Americans diagnosed with invasive breast cancer ~40,890 will die of their disease Breast cancer risk
More informationRSNA, /radiol Appendix E1. Methods
RSNA, 2016 10.1148/radiol.2016151097 Appendix E1 Methods US and Near-infrared Data Acquisition Four optical wavelengths (740 nm, 780 nm, 808 nm, and 830 nm) were used to sequentially deliver the light
More informationImmunohistochemical studies (ER & Ki-67) in Proliferative breast lesions adjacent to malignancy
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 13, Issue 3 Ver. IV. (Mar. 2014), PP 84-89 Immunohistochemical studies (ER & Ki-67) in Proliferative
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationAMSER Case of the Month: November 2018
AMSER Case of the Month: November 2018 52 year old female with an abnormal screening mammogram Areeg Rehman, MS 4 Nova Southeastern University Rebecca T. Sivarajah, MD Penn State University College of
More informationResection Margins in Breast Conserving Surgery. Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland
Resection Margins in Breast Conserving Surgery Alberto Costa, MD Canton Ticino Breast Unit Lugano, Switzerland Breast Conserving Surgery 1 Probably one of the most important innovation in cancer surgery
More informationFlat Epithelial Atypia
Flat Epithelial Atypia Richard Owings, M.D. University of Arkansas for Medical Sciences Department of Pathology Flat epithelial atypia can be a difficult lesion May be a subtle diagnosis Lots of changes
More informationImaging Surveillance in Women with a History of Treated Breast Cancer. Wei Tse Yang, M.D.
Imaging Surveillance in Women with a History of Treated Breast Cancer Wei Tse Yang, M.D. Breast Cancer 1. Extent 2. Response 3. Recurrence Surveillance Breast Cancer 1. Extent 2. Response Surveillance
More informationManagement of Ductal Carcinoma In Situ
Management of Ductal Carcinoma In Situ Stella Hetelekidis, MD Stuart J. Schnitt, MD Monica Morrow, MD Jay R. Harris, MD Introduction Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma,
More informationBreast Imaging: Multidisciplinary Approach. Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina
Breast Imaging: Multidisciplinary Approach Madelene Lewis, MD Assistant Professor Associate Program Director Medical University of South Carolina No Disclosures Objectives Discuss a multidisciplinary breast
More informationPapillary Lesions of the Breast
Papillary Lesions of the Breast Laura C. Collins, M.D. Associate Professor of Pathology Associate Director, Division of Anatomic Pathology Beth Israel Deaconess Medical Center and Harvard Medical School
More informationACCME/Disclosures. Cribriform Lesions of the Prostate. Case
Cribriform Lesions of the Prostate Ming Zhou, MD, PhD Departments of Pathology and Urology New York University Langone Medical Center New York, NY Ming.Zhou@NYUMC.ORG ACCME/Disclosures The USCAP requires
More informationHow to Use MRI Following Neoadjuvant Chemotherapy (NAC) in Locally Advanced Breast Cancer
Global Breast Cancer Conference 2016 & 5 th International Breast Cancer Symposium April 29 th 2016, 09:40-10:50 How to Use MRI Following Neoadjuvant Chemotherapy (NAC) in Locally Advanced Breast Cancer
More informationCurrent Strategies in the Detection of Breast Cancer. Karla Kerlikowske, M.D. Professor of Medicine & Epidemiology and Biostatistics, UCSF
Current Strategies in the Detection of Breast Cancer Karla Kerlikowske, M.D. Professor of Medicine & Epidemiology and Biostatistics, UCSF Outline ν Screening Film Mammography ν Film ν Digital ν Screening
More informationAtypical proliferative lesions diagnosed on core biopsy - 6 year review
Atypical proliferative lesions diagnosed on core biopsy - 6 year review Dr Angela Harris, Dr Julie Weigner & Dr Ricardo Vilain NSW Health Pathology Pathology North, Hunter Anatomical Pathology & Cytology
More informationMinimizing Errors in Diagnostic Pathology
Shahla Masood, M.D. Professor and Chair Department of Pathology and Laboratory Medicine University of Florida College of Medicine-Jacksonville Medical Director, Shands Jacksonville Breast Health Center
More informationAna Sofia Preto 19/06/2013
Ana Sofia Preto 19/06/2013 Understanding the underlying pathophysiologic processes leading to the various types of calcifications Description and illustration of the several types of calcifications, according
More informationLeonard M. Glassman MD Analysis of Breast Calcifications
Importance of Calcification Leonard M. Glassman MD FACR American Institute for Radiologic Pathology Washington Radiology Associates, PC Washington DC 45% of all breast cancers present as calcification
More informationCPC 4 Breast Cancer. Rochelle Harwood, a 35 year old sales assistant, presents to her GP because she has noticed a painless lump in her left breast.
CPC 4 Breast Cancer Rochelle Harwood, a 35 year old sales assistant, presents to her GP because she has noticed a painless lump in her left breast. 1. What are the most likely diagnoses of this lump? Fibroadenoma
More informationImmunohistochemical classification of breast tumours
Immunohistochemical classification of breast tumours Workshop in Diagnostic Immunohistochemistry September 19 th - 21 th 2018 Anne-Vibeke Lænkholm Department of Surgical Pathology, Zealand University Hospital,
More informationInvasive Papillary Breast Carcinoma
410 This is an Open Access article licensed under the terms of the Creative Commons Attribution- NonCommercial-NoDerivs 3.0 License (www.karger.com/oa-license), applicable to the online version of the
More information1 NORMAL HISTOLOGY AND METAPLASIAS
1 NORMAL HISTOLOGY AND METAPLASIAS, MD Anatomy and Histology 1 Metaplasias 2 ANATOMY AND HISTOLOGY The female breast is composed of a branching duct system, which begins at the nipple with the major lactiferous
More informationBreast Cancer. For breast cancer, the mortality risk varies with the stage of the cancer.
CREATED EXCLUSIVELY FOR FINANCIAL PROFESSIONALS Rx FOR SUCCESS Breast Cancer Breast cancer is the most common cancer in women in the United States and second only to lung cancer as a cause of cancer deaths.
More informationEvaluation & Management of PowerPoint Cover Title. the High Risk Population. High Risk Clinic
Evaluation & Management of PowerPoint Cover Title the High Risk Population High Risk Clinic Subtitle Joanna Would Springman, Go Here PA-C Assessment Genetics Known genetic mutation Family history with
More informationRecurrence, new primary and bilateral breast cancer. José Palacios Calvo Servicio de Anatomía Patológica
Recurrence, new primary and bilateral breast cancer José Palacios Calvo Servicio de Anatomía Patológica Ipsilateral Breast Tumor Relapse (IBTR) IBTR can occur in approximately 5 20% of women after breast-conserving
More informationBREAST SURGERY PROGRESS TEST Name:
General Surgery Residency Program Excellent surgeons BREAST SURGERY PROGRESS TEST Name: Choose the BEST answer for the following questions. 1. All of the following factors are associated with an increased
More informationDiseases of the breast (2 of 2) Breast cancer
Diseases of the breast (2 of 2) Breast cancer Epidemiology & etiology The most common type of cancer & the 2 nd most common cause of cancer death in women 1 of 8 women in USA Affects 7% of women Peak at
More information